Business
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in
About this update from Pliant Therapeutics, Inc.
[{"type":"text","content":"- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC - INTEGRIS-IPF 320 mg dose 24-week data expected in the second quarter of 2023 - $287.5 million equity financing extends runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results. \"2022 was a transformative year for Pliant. We delivered positive interim data from our Phase 2a INTEGRIS-IPF trial, strengthened our financial position with our first follow-on financing and continued to advance our clinical- and early-stage portfolio. We are positioned to deliver multiple clinical catalysts in 2023,\" said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. \"2023 has already been productive with the release of additional positive data from the INTEGRIS-IPF 320 mg cohort, where bexotegrast displayed a continued favorable safety profile and outperformed all lower dose cohorts on exploratory efficacy endpoints. We look forward to sharing additional clinical data readouts and portfolio milestones throughout the remainder of this year.\" Fourth Quarter and Recent Highlights Bexotegrast (PLN-74809) Highlights INTEGRIS-IPF Phase 2a clinical data from bexotegrast 320 mg dose group at 12 weeks showed bexotegrast was well tolerated and demonstrated statistically significant forced vital capacity (FVC) increases at all time points in patients with idiopathic pulmonary fibrosis (IPF). Bexotegrast at 320 mg was well tolerated with no drug-related severe or serious adverse events and showed dose-proportional increases in plasma concentrations, consistent with prior studies. Exploratory efficacy endpoints demonstrated strong treatment effects on FVC, Quantitative Lung Fibrosis (QLF) imaging and biomarkers over 12 weeks. In addition, no bexotegrast-treated patients experienced disease progression as defined by FVC percent predicted (FVCpp) decline of greater than or equal to 10%, a risk factor associated with increased mortality in IPF patients.INTEGRIS-IPF Pha...